NCT04524052View on ClinicalTrials.gov

To Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of DWRX2003 Against COVID-19

PHASE1UnknownINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 31, 2020

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Healthy
Interventions
DRUG

DWRX2003

Intramuscularly injection at pre-defined injection sites

DRUG

Placebo

Intramuscularly injection at pre-defined injection sites

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY